Last reviewed · How we verify
Drug: PRC-063
PRC-063 is an extended-release formulation of methylphenidate designed to provide sustained dopamine and norepinephrine reuptake inhibition for ADHD symptom management.
PRC-063 is an extended-release formulation of methylphenidate designed to provide sustained dopamine and norepinephrine reuptake inhibition for ADHD symptom management. Used for Attention-deficit/hyperactivity disorder (ADHD) in children and adults.
At a glance
| Generic name | Drug: PRC-063 |
|---|---|
| Also known as | Methylphenidate |
| Sponsor | Rhodes Pharmaceuticals, L.P. |
| Drug class | Stimulant; dopamine-norepinephrine reuptake inhibitor |
| Target | Dopamine transporter (DAT); norepinephrine transporter (NET) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | Phase 3 |
Mechanism of action
PRC-063 uses a proprietary extended-release technology to deliver methylphenidate over an extended period, allowing for once-daily dosing. By inhibiting the reuptake of dopamine and norepinephrine in the central nervous system, it enhances neurotransmitter availability to improve attention, focus, and impulse control in patients with ADHD.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD) in children and adults
Common side effects
- Decreased appetite
- Insomnia
- Headache
- Abdominal pain
- Increased heart rate
- Anxiety
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |